PML/RARα-positive leukemia models are based on a transgenic approach driven by regulatory elements of cathepsin G or hMPR8, or a knock-in [10-13], as well as on transduction/transplantation models [5, 9, 14]. This evidence concerns the gene RARA and leukemia.